EmoTIChealth: a serious game to strengthen emotional skills in teens with and without chronic conditions
Official title: "Promoting Health in Adolescents With and Without Chronic Diseases Through Emotional Development: Design and Implementation of a Serious Game Technology Platform (EmoTIChealth)"
Run by University of Valencia · NCT07212530 · Data updated 2026-11-12
This project will try a digital serious game for 12–16-year-olds to boost socioemotional skills and offer tailored support for teens with asthma, food allergy, type 1 diabetes, or allergic rhinitis.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 12 Years to 16 Years |
| Sex | All |
| Enrollment | 600 (estimated) |
| Sponsor | University of Valencia Academic / other |
| Locations | 1 site (Valencia, Valencia) |
| Status | Recruiting |
| Started | December 1, 2025 |
| Main results expected | August 30, 2027 |
| Study ends | August 30, 2027 |
| Registry record updated | May 13, 2026 |
| Trial ID | NCT07212530 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are Spanish-speaking adolescents aged 12–16 who can consent with their parents/guardians, have internet access, and either are healthy or have asthma, food allergy, type 1 diabetes, or allergic rhinitis.
✕Probably not a fit
Those without reliable internet access, non–Spanish speakers, or adolescents whose needs require intensive in-person mental-health care are unlikely to benefit from this digital program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
EmoTIChealth is a digital intervention delivered as a serious game platform aimed at promoting psycho-emotional health in adolescents aged 12–16. The program combines universal health-promotion content for general adolescent development with specific modules tailored to young people living with chronic conditions such as asthma, food allergy, type 1 diabetes, and allergic rhinitis. The platform is designed to build personal resources and provide psychological support during a key developmental stage, with content accessible online and requiring internet access. Enrollment and oversight occur through the University of Valencia site in Valencia, Spain, and participation requires Spanish language proficiency.
Why it matters
Potential benefit: If successful, the program could improve socioemotional skills, reduce future emotional difficulties, and offer tailored psychological support that may help adolescents better manage chronic conditions.
How similar studies have gone: Similar serious-game and digital psychoeducation programs for adolescent mental health have shown promising but mixed results, while condition-specific digital modules for chronic illnesses are less extensively validated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Informed consent by parents/guardians and participants. * Aged between 12 and 16 years old Exclusion Criteria: * No access to internet or new technologies * Not a Spanish speaker.
Where it's running
-
Facultat de Psicología
Valencia, Valencia, Spain Recruiting
Study contacts
- Principal investigator: Marián Pérez-Marín, PHD — Universitat de Valencia
- Study coordinator: Marián Pérez-Marín, PHD
- Email: marian.perez@uv.es
- Phone: 0034 9639
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Evaluating the effects of RG-RV16 inoculation on airway health
This study is testing whether a new inoculation can improve airway health in people with allergies, asthma, and those without any respiratory issues.
-
Chronic Respiratory Disease Participant Engagement
This study tests whether adults with long-term lung conditions can get comfortable with a clinical trials unit and research team before joining future trials.
-
Mannan-Conjugated Allergoids for House Dust M mite Allergy
A new treatment named EP-088_MM09 is being tested to see if it can reduce nasal and eye allergy symptoms (and possibly asthma) in people aged 12 to 65 who are allergic to house dust mites, compared with a placebo.
-
Mannan-conjugated Allergoids for House Dust Mite Allergy
A new treatment called EP-088_MM09 is being tested to see if it can reduce allergy symptoms in people with house dust mite–related nasal allergy, with or without mild asthma.
-
HB0056 in adults with moderate to severe asthma
This study tests HB0056 versus a placebo to see if it helps adults with moderate to severe asthma reduce rescue inhaler use and improve symptoms.
-
Semaglutide on body composition in adults with type 1 diabetes and overweight/obesity
This study tests whether weekly semaglutide changes body composition in adults with type 1 diabetes who are overweight or obese, compared with a placebo over 24 weeks.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.